{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:48Z","timestamp":1760144568982,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.cjca.2012.07.006","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T01:49:15Z","timestamp":1347673755000},"page":"659-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transitioning Between Endothelin Receptor Blockers: Monitoring to Ensure a Smooth Transition"],"prefix":"10.1016","volume":"29","author":[{"given":"Nancy","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2012.07.006_bib1","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.07.006_bib2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2012.07.006_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2012.07.006_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1183\/09059180.00008411","article-title":"Pulmonary hypertension: the science behind the disease spectrum","volume":"21","author":"Wilkins","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cjca.2012.07.006_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1139\/y03-008","article-title":"The endothelin system in pulmonary hypertension","volume":"81","author":"Michel","year":"2003","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.cjca.2012.07.006_bib6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1164\/rccm.201108-1562OC","article-title":"Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension","volume":"185","author":"Marsboom","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.07.006_bib7","first-page":"672","article-title":"Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension","volume":"29","author":"Fox","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2012.07.006_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000102534","article-title":"Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions","volume":"44","author":"Sauvageau","year":"2007","journal-title":"J Vasc Res"},{"key":"10.1016\/j.cjca.2012.07.006_bib9","first-page":"A4743","article-title":"Inhibition of endothelin-1 levels by treprostinil is counteracted by bostentan and ambrisentan in smooth muscle cells derived from patients with pulmonary arterial hypertension","volume":"185","author":"Patel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.07.006_bib10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.07.006_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2012.07.006_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1378\/chest.124.1.247","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study","volume":"124","author":"Sitbon","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.07.006_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.07.006_bib14","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"year":"2010","series-title":"Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury [press release]","key":"10.1016\/j.cjca.2012.07.006_bib15"},{"key":"10.1016\/j.cjca.2012.07.006_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1139\/Y10-060","article-title":"Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes","volume":"88","author":"Hartman","year":"2010","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.cjca.2012.07.006_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/VHRM.S15026","article-title":"Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension","volume":"7","author":"Safdar","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.cjca.2012.07.006_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.07.006_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2012.07.006_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2010.11.020","article-title":"Compelling evidence of long-term outcomes in pulmonary arterial hypertension?","volume":"57","author":"Gomberg-Maitland","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.07.006_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.07.006_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2012.07.006_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.07.006_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ahj.2012.01.024","article-title":"Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension","volume":"163","author":"Ryan","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2012.07.006_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1378\/chest.130.5.1481","article-title":"Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment","volume":"130","author":"Fisher","year":"2006","journal-title":"Chest"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1200339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1200339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:37:49Z","timestamp":1760107069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X1200339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0828282X1200339X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2012.07.006","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transitioning Between Endothelin Receptor Blockers: Monitoring to Ensure a Smooth Transition","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2012.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}